Siddhars Sharma New Delhi [India], July 3 (ANI): Friday’s parliamentary party hunted down the central government over the price dispute over covaxin in Brazil and asked the center why it was “significantly silent” on the issue.

Parliamentary spokesman Spryya Sulinate briefed Mediperson: “It’s important to raise these questions because Bharat Biotech may be a private sector, but public funding is not available. It was diverted to the development of this vaccine, which is why we have the right to ask: what happened with that money, and why is the government so silent about it? ” Parliamentary leaders said Bharat Biotech had agreed with Brazil’s Precisa Medicamentos and signed a contract they would supply 20 million doses to the country. However, media reports indicate that Bharat Biotech has estimated the price of covacin at $ 1.34 per dose, raising it to $ 15 per dose. Brazilian opponents and the Senate have raised the issue, and criminal investigation agencies have since investigated the issue. The Brazilian agency is also investigating the diversion of potential offshore funds by an entity called Madison Biotech related to Bharat Biotech.

She further stated that the problem was that the ICMR was going to get 5 percent of the profit from the sale of Covacin. However, there are claims that Bharat Biotech sold the vaccine to Madison Biotech at a low price.

“Madison has earned most of the profits. We really want to know what the relationship between Madison Biotech and Barrat Biotech is. These claims are of a very serious nature. And whether Bharat Biotech was selling at a low price as claimed, then the ICMR’s own profits have clearly fallen. “

“There is a allegation that Madison Biotech has requested an offshore payment of US $ 45 million. Why is this Bharat Biotech” partner “requesting this kind of money? It is illegal because it is not part of a contract signed between Bharat Biotech. Presisa Medicamentos and the Brazilian Government. “

Parliamentary leaders emphasized that if these claims should be believed, it is a serious issue of corporate governance. Whether Madison Biotech is an export sector, a logistics company, or a family-owned venture, it should be known. “We want to know, as it is now established that the founder of Bharat Biotech is also the co-founder of Madison Biotech,” she insisted.

Parliamentary leaders said the issue would bring disappointment and pollution to the country’s pride throughout the Indian pharmaceutical industry. She said the issue could be treated as a PMLA case (Money Laundering Prevention Act, 2002) or a SFIO (Serious Fraud Investigation Agency) case.

“If there is a diversion of funds, this is the case for PMLA. The decline in profits and the irregularity of tax restraints are the case for SFIO. Why aren’t those investigations ordered? This is the tax Isn’t it the case of diversion and misappropriation of funds? Criminal investigations and parliamentary investigations have been initiated against the contract by the Brazilian government, why is the Indian government so silent? “She asked.

Parliamentary leaders asked the central government on June 4, when exports of these vaccines were totally banned, whether special approval was given to the export of vaccines. “What happened?” She asked. (ANI)